Article
Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.
European journal of clinical pharmacology - 1 Nov 2024
Kole Ismail Hasan, Vural Pınar, Yurdacan Beste, Alemdar Adem, Mutlu Caner
Abstract excerpt
BACKGROUND: There is insufficient replicated data to establish a relationship between the polymorphisms of SLC6A2 and CYP2D6 and the treatment responses of atomoxetine (ATX) in ADHD. We focused on evaluating the effect of top-line single nucleotide polymorphisms (SNPs) in SLC6A2 and CYP2D6 on the ATX treatment response in attention deficit and hyperactivity disorder (ADHD). METHODS: Of 160 patient records, 34...
Topics
Join the communities discussing this publication.